The findings from the Medidata-commissioned survey confirm that AI implementation in clinical trials has moved firmly beyond theoretical discussion.
Benedict Cross, Chief Technology Officer at PhoreMost, discusses targeted protein degradation.
Omnichannel didn’t fail pharma. Our metrics did. In 2026, fixing that won’t be optional.
The ICER threshold increase is expected to allow an additional three to five medicines or indications each year to be recommended for NHS use.
According to Deloitte’s 2026 Life Sciences Outlook Survey, the life sciences sector might be becoming increasingly borderless, but only 41% of responding biopharma and medtech executives fe
Editor's Picks
